AU2002212897A1 - N-type calcium channel antagonists for the treatment of pain - Google Patents

N-type calcium channel antagonists for the treatment of pain

Info

Publication number
AU2002212897A1
AU2002212897A1 AU2002212897A AU1289702A AU2002212897A1 AU 2002212897 A1 AU2002212897 A1 AU 2002212897A1 AU 2002212897 A AU2002212897 A AU 2002212897A AU 1289702 A AU1289702 A AU 1289702A AU 2002212897 A1 AU2002212897 A1 AU 2002212897A1
Authority
AU
Australia
Prior art keywords
pain
treatment
type calcium
calcium channel
channel antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002212897A
Inventor
Marc Chapdelaine
Lucius Kemp
John Mccauley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2002212897A1 publication Critical patent/AU2002212897A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compounds having selective action at neuronal N-type calcium channels useful for the treatment of pain in accord with the following structural diagram,wherein R<1>, R<2 >and R<3 >are a variety of groups as defined in the specification.
AU2002212897A 2000-11-06 2001-10-31 N-type calcium channel antagonists for the treatment of pain Abandoned AU2002212897A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0004056A SE0004056D0 (en) 2000-11-06 2000-11-06 N-type calcium channel antagonists for the treatment of pain
SE0004056 2000-11-06
PCT/SE2001/002391 WO2002036569A1 (en) 2000-11-06 2001-10-31 N-type calcium channel antagonists for the treatment of pain

Publications (1)

Publication Number Publication Date
AU2002212897A1 true AU2002212897A1 (en) 2002-05-15

Family

ID=20281716

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002212897A Abandoned AU2002212897A1 (en) 2000-11-06 2001-10-31 N-type calcium channel antagonists for the treatment of pain

Country Status (9)

Country Link
US (1) US6841680B2 (en)
EP (1) EP1339690B1 (en)
JP (1) JP2004513118A (en)
AT (1) ATE421502T1 (en)
AU (1) AU2002212897A1 (en)
DE (1) DE60137534D1 (en)
ES (1) ES2319259T3 (en)
SE (1) SE0004056D0 (en)
WO (1) WO2002036569A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862301B1 (en) * 2003-11-17 2007-12-21 Aventis Pharma Sa NEW PROCESS FOR THE PREPARATION OF 3-FLUORINATED QUINOLINES
CA2603926A1 (en) * 2005-04-08 2006-10-12 Neuromed Pharmaceuticals Ltd. Combination therapy comprising an n-type calcium channel blocker for the alleviation of pain
US8362021B2 (en) * 2006-05-11 2013-01-29 Zalicus Pharmaceuticals Ltd. Method for increasing the bioavailability of benzhydryl piperazine containing compounds
US9249101B2 (en) * 2010-10-29 2016-02-02 Clino Ltd. Tau imaging probe
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
WO2012122279A1 (en) 2011-03-08 2012-09-13 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
DE102016125645A1 (en) * 2016-12-23 2018-06-28 Forschungszentrum Jülich GmbH D-enantiomeric peptides for the treatment of chronic and neuropathic pain

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0597003A1 (en) * 1991-08-02 1994-05-18 Pfizer Inc. Quinoline derivatives as immunostimulants

Also Published As

Publication number Publication date
US6841680B2 (en) 2005-01-11
EP1339690B1 (en) 2009-01-21
WO2002036569A1 (en) 2002-05-10
ATE421502T1 (en) 2009-02-15
DE60137534D1 (en) 2009-03-12
US20040053965A1 (en) 2004-03-18
SE0004056D0 (en) 2000-11-06
JP2004513118A (en) 2004-04-30
EP1339690A1 (en) 2003-09-03
ES2319259T3 (en) 2009-05-06

Similar Documents

Publication Publication Date Title
AU2002212894A1 (en) N-type calcium channel antagonists for the treatment of pain
AU2001238596A1 (en) 18607, a novel human calcium channel
AU2002212202A1 (en) Dynamic channel selection scheme for idee 802.11 wlans
HUS1400046I1 (en) 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES
EP1129089A4 (en) Spiro-indolines as y5 receptor antagonists
AU2001239725A1 (en) Antibacterial agents
BE2011C037I2 (en)
AU2002213273A1 (en) Stenoprophiluric matrices, and methods of making and using the same
AU7451300A (en) Thermoplastic elastomer, use thereof, and process for producing the same
MXPA02006826A (en) Cell division inhibitors and process for producing the same.
ZA9710796B (en) Oxyiminopregnanecarbolactones.
AU2001294228A1 (en) Benzimidazole compounds, process for producing the same and use thereof
AU2002219664A1 (en) Microorganism Producing L-Lysine And Processes For Producing L-Lysine Using The Same
SE0102858D0 (en) N-type calcium channel antagonists for the treatment of pain
SE0004054D0 (en) N-type calcium channel antagonists for the treatment of pain
AU2002212897A1 (en) N-type calcium channel antagonists for the treatment of pain
AU2002368133A1 (en) 1,3-azole derivative and medicinal composition containing the derivative for treatment for thombosis
PL351616A1 (en) Polyolefin compositions, method for the production and use thereof
AU2003215190A1 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
GB2324091A (en) Metalloproteinase inhibitors
WO2000034285A3 (en) Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers
AU1772299A (en) Well treatment with microorganisms
AU3880399A (en) Octahydropyrrolo-(3,4-c)carbazoles useful as analgesic agents
SE0004055D0 (en) N-type calcium channel antagonists for the treatment of pain
EP1083914A4 (en) Treatment of arthritis and other similar conditions